期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER-2阳性晚期乳腺癌治疗策略 被引量：6

Therapeutic strategy for HER-2-positive advanced breast cancer
下载PDF
导出
摘要 HER-2阳性晚期乳腺癌患者预后差,以抗HER-2靶向治疗为基础的综合治疗显著延长了患者的生存期、改善了预后。目前多种抗HER-2靶向药物已应用于临床,抑制HER-2通路是HER-2阳性晚期乳腺癌患者一线治疗及一线治疗进展后的基础治疗。本文简要介绍HER-2阳性晚期乳腺癌治疗相关的关键临床研究、指南推荐及今后的研究方向,以指导临床实践。 Patients with HER-2-positive advanced breast cancer were associated with poor prognosis. Meanwhile, HER-2-targeted ther- apy has dramatically improved survival and prognosis among breast cancer patients. Over the years, multiple HER-2-targeting drugs stepped into clinical practice, and the targeted agents are now considered as the standard of care in the first-line setting and beyond. This review basically summarizes the importance of HER-2-targeted therapy, the significance of the clinical trial results, and the clinical practice guidelines for the management of patients with HER-2-positive advanced breast cancer.
作者 孙婧 张频
机构地区 中国医学科学院肿瘤医院肿瘤内科
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2016年第10期412-417,共6页 Chinese Journal of Clinical Oncology
关键词 HER-2阳性 晚期乳腺癌 治疗策略 临床研究 靶向治疗 HER-2-positive, advanced breast cancer, therapeutic strategy, clinical trials, targeted therapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER-2 status and trastuzumab treatment: an institutional-based review[J]. J Clin Oncol, 2010, 28(1):92-98.
  • 2Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network [J]. Nat Rev Mol Cell Biol, 2001, 2(2):127-137.
  • 3De Mattos-Arruda L, Cortes J. Use of pertuzumab for the treat- ment of HER-2 positive metastatic breast cancer[J]. Adv Ther, 2013, 30(7):645-658.
  • 4Segovia-Mendoza M, Gonzlez-Gonzlez ME, Barrera D, et al. Effi- cacy and mechanism of action of the tyrosine kinase inhibitors 6efi- tinib, lapatinib and neratinib in the treatment of HER-2 positive breast cancer: preclinical and clinical evidence[J]. Am J Cancer Res, 2015, 5(9):2531-2561.
  • 5Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J]. N Engl J Med, 2001, 344(11):783-792.
  • 6Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal 8rowth factor receptor 2-posi- tive metastatic breast cancer administered as first-line treatment: the M77001 study eroup[J]. J Clin Oncol, 2005, 23(19):4265-4274.
  • 7Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressin8 metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18):2786-2792.
  • 8Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER-2-positive meta- static breast cancer[J]. J Clin Oncol, 2020, 28(6):976-983.
  • 9Baselga J, Geimon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J]. J Clin Oncol, 2020, 28(7):2138-2244.
  • 10Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.

共引文献1183

同被引文献63

二级引证文献55

中国肿瘤临床
2016年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部